Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

37 results about "Polycystic liver disease" patented technology

Polycystic liver disease (PLD) usually describes the presence of multiple cysts scattered throughout normal liver tissue. PLD is commonly seen in association with autosomal-dominant polycystic kidney disease, with a prevalence of 1 in 400 to 1000, and accounts for 8–10% of all cases of end stage renal disease. The much rarer autosomal-dominant polycystic liver disease will progress without any kidney involvement.

Method of examining polycystic kidney disease and method of screening for therapeutic agent of the disease

The present invention provides a method of examining polycystic kidney disease or a complication of polycystic kidney disease using a gene(s) selected from the group consisting of NTNG1, POSTN, TNC, KAL1, BST1, ACAT2, INSIG1, SCD, HSD3B1, KRT7, USP40, SULT1E1, BMP6, CD274, CTGF, E2F7, EDN1, FAM43A, FRMD3, MMP10, MYEOV, NR2F1, NRCAM, PDCK1, PLXNA2, SLC30A3, SNAI1, SPOCD1, MMP1, TFPI2, HMGA2, KRTAP4-7, KRTAP4-8, KRTAP4-9, MYPN, RPPH1, and SIAE, and a method of screening for a therapeutic agent or a preventive agent therefore, and further vascular endothelial cells or vascular mural cells obtained via differentiation induction from iPS cells formed from a somatic cell of a subject suffered from polycystic kidney disease and having cerebral aneurysm as a complication.
Owner:KYOTO UNIV

Polycystic kidney disease 1 gene and uses thereof

The present invention relates to the polycystic kidney disease 1 (PKD1) gene and its nucleic acid sequence, mutations thereof in patients having PKD1-associated disorders, the protein encoded by the PKD1 gene or its mutants, and their uses in disease diagnosis and therapy.
Owner:ERASMUS UNIVERSITY ROTTERDAM +3

Medical use of pentacyclic triterpenoid saponin and pharmaceutical composition thereof

The present invention discloses an application of pentacyclic triterpenoid saponin represented by formulas (I) to (XIII) for the preparation of a medicine for preventing or treating AMPK-mediated diseases including fatty liver disease, inflammatory bowel disease, respiratory disease, diabetic complications and polycystic kidney disease. The compounds of formula (I) to (XIII) are especially usefulfor nonalcoholic simple fatty liver, nonalcoholic steatohepatitis, non-alcoholic steatohepatitis-induced cirrhosis, ulcerative colitis, Crohn's disease, chronic obstructive Pulmonary diseases, asthma,idiopathic pulmonary fibrosis, cystic fibrosis, allergic rhinitis, diabetic nephropathy, diabetic cardiomyopathy, diabetic ulcers, and autosomal dominant polycystic kidney disease. A pharmaceutical composition for preventing and treating the AMPK-mediated diseases of the present invention comprises a therapeutically effective amount of the compounds of the formula (I) to (XIII) or a pharmaceutically acceptable salt or a solvate thereof as an active ingredient and a pharmaceutically acceptable excipient.
Owner:CHINA PHARM UNIV

Detection and treatment of polycystic kidney disease

Compositions useful for examining the PKD1 gene are provided. In addition, methods for detecting mutations of the PKD1 gene, which can be associated with autosomal dominant polycystic kidney disease in humans, are provided. Methods for diagnosing a mutant PKD1 gene sequence in a subject also are provided, as are methods of treating a subject having a PKD1-associated disorder.
Owner:THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE

Novobiocin analogues and treatment of polycystic kidney disease

InactiveUS20110082098A1Reduction of cyst formationBiocideCarbohydrate active ingredientsNovobiocinCyst formation
Novobiocin analogues are useful in methods of treating, inhibiting, and / or preventing cyst formation in autosomal dominant polycystic kidney disease (ADPKD) in a subject. The disclosure provides methods of treating ADPKD comprising administering a therapeutically effective amount of a coumarin-3-carboxamide novobiocin analogue. Accordingly, the method can include administering a novobiocin analogue in a therapeutically effective amount for reducing levels of mTOR pathway phosphoproteins P-mTOR, P-Akt and P-S6K, or combinations thereof. Further, the method can include administering a novobiocin analogue in a therapeutically effective amount for reducing levels of Hsp-90 client proteins CFTR, ErbB2, c-Raf and Cdk4, or combinations thereof.
Owner:UNIVERSITY OF KANSAS

Imidazolyl derivatives

The present invention is directed to imidazolyl derivatives of the formula: where the substituents are defined in the specification, or a pharmaceutically acceptable salt thereof. The derivatives bind selectively to the somatostatin subtype receptors and elicit either an agonist or antagonist effect from the somatostatin subtype receptors. The derivatives are useful for treating a variety of diseases including acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, VIPoma, nesidoblastosis, hyperinsulinism, gastrinoma, Zollinger-Ellison Syndrome, diarrhea, AIDS related diarrhea, chemotherapy related diarrhea, scleroderma, Irritable Bowel Syndrome, pancreatitis, small bowel obstruction, gastroesophageal reflux, duodenogastric reflux, Cushing's Syndrome, gonadotropinoma, hyperparathyroidism, Graves' Disease, diabetic neuropathy, Paget's disease, polycystic ovary disease, cancer, cancer cachexia, hypotension, postprandial hypotension, panic attacks, GH secreting adenomas or TSH secreting adenomas.
Owner:IPSEN PHARMA SAS

Drug for preventing and/or treating polycystic kidney disease

An object of the present invention is to provide a combination drug that has remarkably excellent preventive and / or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and / or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug.
Owner:OTSUKA PHARM CO LTD

Spiroindoline derivatives as gonadotropin- releasing hormone receptor antagonists

Spiroindoline derivatives, process for their preparation and pharmaceutical compositions thereof, their use for the treatment and / or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and / or prophylaxis of diseases, especially sex-hormone-related diseases in both men and women, in particularly those selected from the group of endometriosis, uterine fibroids, polycystic ovarian disease, hirsutism, precocious puberty, gonadal steroid-dependent neoplasia such as cancers of the prostate, breast and ovary, gonadotrope pituitary adenomas, sleep apnea, irritable bowel syndrome, premenstrual syndrome, benign prostatic hypertrophy, contraception and infertility (e.g., assisted reproductive therapy such as in vitro fertilization). The present application relates in particular to spiroindoline derivatives as gonadotropin-releasing hormone (GnRH) receptor antagonists.
Owner:BAYER INTELLECTUAL PROPERTY GMBH

Detection and treatment of polycystic kidney disease

Compositions useful for examining the PKD1 gene are provided. In addition, methods for detecting mutations of the PKD1 gene, which can be associated with autosomal dominant polycystic kidney disease in humans, are provided. Methods for diagnosing a mutant PKD1 gene sequence in a subject also are provided, as are methods of treating a subject having a PKD1-associated disorder.
Owner:THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE

Application of EZH2 (enhancer of zeste homolog 2) in preparation of drugs to prevent or treat polycystic kidney disease

InactiveCN109966479AConfirmed inhibitionEZH2 inhibitory inhibition confirmedPeptide/protein ingredientsTransferasesEZH2Polycystic liver disease
The invention relates to the technical field of medicine, in particular to application of EZH2 (enhancer of zeste homolog 2) in the preparation of drugs to prevent or treat polycystic kidney disease.It is discovered herein that an EZH2 inhibitor can inhibit the proliferation of cyst cells by inducing the apoptosis of polycystic kidney disease cyst lining epithelial cells and regulating cell cycle, and can protect the renal function by inhibiting the growth of renal cysts and enlargement of renal size. It is indicated that EZH2 can act as a novel target for autosomal dominant polycystic kidneydisease and is very significant to the treatment of polycystic kidney disease; the EZH2 inhibitor can be used to develop new pilot compounds to prevent or treat autosomal dominant polycystic kidney disease and can also be used to prepare drugs to prevent or treat autosomal dominant polycystic kidney disease.
Owner:SHANGHAI CHANGZHENG HOSPITAL +1

Somatostatin agonists

The present invention is directed to cyclic peptides of formula (I): X-A1-cyclo(D-Cys-A3-A4-Lys-A6-A7)-A8-Y, or a pharmaceutically acceptable salt thereof. The peptides bind selectively to the somatostatin subtype receptor type-5 and elicit an agonist effect from the somatostatin subtype receptors. The peptides are useful for treating a variety of diseases, including Cushings Syndrome, gonadotropinoma, hyperparathyroidism, Paget's disease, VIPoma, nesidioblastosis, hyperinsulinism, gastrinoma, Zollinger-Ellison Syndrome, hypersecretory diarrhea related to AIDS and other conditions, irritable bowel syndrome, pancreatitis, Crohn's Disease, systemic sclerosis, thyroid cancer, psoriasis, hypotension, panic attacks, sclerodoma, small bowel obstruction, gastroesophageal reflux, duodenogastric reflux, Graves' Disease, polycystic ovary disease, upper gastrointestinal bleeding, pancreatic pseudocysts, pancreatic ascites, leukemia, meningioma, cancer cachexia, acromegaly, restenosis, hepatoma, lung cancer, melanoma, inhibiting the accelerated growth of a solid tumor, decreasing body weight, treating insulin resistance, Syndrome X, prolonging the survival of pancreatic cells, fibrosis, hyperlipidemia, hyperamylinemia, hyperprolactinemia and prolactinemia.
Owner:IPSEN PHARMA SAS

Methods for treating polycystic kidney disease and polycystic liver disease

The present invention provides compounds of Formula (I) or (II), which are thought to be able to inhibit mTOR (mammalian target of rapamycin) signaling pathway, induce UPR (unfolded protein response), and / or perturb mitochondrial function of a cyst cell (e.g., a cyst cell causing polycystic kidney disease (PKD, e.g., autosomal dominant PKD (ADPKD) or autosomal recessive PKD (ARPKD)) or polycystic liver disease (PLD, e.g., autosomal dominant PLD (ADPLD) or autosomal recessive PLD (ARPLD)). The invention also provides pharmaceutical compositions, kits, and methods involving the compounds described herein for use in treating PKD or PLD, inhibiting the growth of a cyst cell, and / or killing a cyst cell.
Owner:YALE UNIV +1

Application of tripterine in preparation of medicines for treating cholestatic liver disease

The invention discloses application of tripterine in preparation of medicines for treating cholestatic liver disease. The tripterine achieves obvious effects of improving cholestasis and alleviating liver damage on intrahepatic cholestasis induced by mouse alpha-naphthylisothiocyanate (ANIT) and cholestatic liver disease induced by thioacetamide (TAA), can obviously lower levels of aspartic transaminase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP) in plasma of two models, reduce the cholic acid content in the plasma and promote bile excretion and has the effects of protecting liver and increasing choleresis; and when being applied to research and development of medicines with effects of protecting liver and increasing choleresis, the tripterine can create excellent economic benefits and wide social benefits.
Owner:KUNMING INST OF BOTANY - CHINESE ACAD OF SCI

Screening methods for compounds useful in the treatment of polycystic kidney disease

The present invention provides cell-based screening assays designed to identify agents that regulate the activity of the polycystic kidney disease proteins encoded by the PKD-1 and PKD-2 genes and that may be useful in the treatment of polycystic kidney disease. The assays of the invention comprise the contacting of genetically engineered cells expressing a mutant or truncated PKD gene product with a test agent and assaying for a decrease in the PKD mediated mutant phenotype. Characteristics associated with such a mutant phenotype include increased adherence to type I collagen coated surfaces; apical expression of NaK-ATPase on the cell membrane; increased expression of β-2-NaK-ATPase; and decreased focal adhesion kinase (FAK) incorporation into focal adhesion complexes, and inability to form tubular structures in a gel matrix. To facilitate the screening methods of the invention, cells may be genetically engineered to express epitope tagged PKD gene products and / or epitope tagged PKD interacting proteins (PKD-IP). Such interacting proteins include, for example, focal adhesion complex proteins such as FAK, paxillin, vinculin, talin and the like.
Owner:MT SINAI SCHOOL OF MEDICINE

Vitamins c and k for treating polycystic diseases

InactiveUS20140200270A1Inhibiting cystogenesisBiocideUrinary disorderCystic diseaseVitamin C
Provided herein are methods for treating, preventing, or ameliorating one or more symptoms of a polycystic disease in a subject, comprising administering to the subject a therapeutically effective amount of vitamins C and K.
Owner:IC MEDTECH CORP

Method of treating or preventing polycystic kidney disease and pkd animal model with exogenous neutrophil gelatinase-associated lipocalin

Disclosed is a method of treating or preventing polycystic kidney disease (PKD) by administration of neutrophil geleatinase-associated lipocalin (Ngal) protein. Also, a transgenic non-human animal model is established to investigate the effect of overexpression of exogenous Ngal on PKD progression.
Owner:NATIONAL TAIWAN NORMAL UNIVERSITY

Methods for treatment of polycystic kidney disease

InactiveUS20190345494A1Increase slowlySlows rate of decline of glomerular filtration ratePeptide/protein ingredientsPharmaceutical delivery mechanismPhysiologyPolycystic liver disease
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST +1

Pharmaceutical composition for alleviating or treating autosomal dominant polycystic kidney disease comprising dna methylation inhibitor

ActiveCN105163741ADelayed cyst formationPeptide/protein ingredientsGenetic material ingredientsCanine kidneyHereditary Mutation
In order to determine epigenetic variations of autosomal dominant polycystic kidney disease and functional association therebetween, the present inventors have subjected individuals with polycystic kidney disease and without polycystic kidney disease to analysis through methylation profiling in random fashion of the genome as a whole. Interestingly, in PKD1 and other genes associated with ion transport and cell adhesion, there was hypermethylation in the gene-body region, and the expression of these genes was down-regulated in polycystic kidney disease. In particular, in PKD1, there was hypermethylation in the polycystic kidney disease gene-body region, and this was associated with MBD2 (methyl-CpG-binding domain 2) protein binding. In addition, DNA methylation inhibitor treatment was accompanied by up-regulation of PKD1 expression and caused a delay in cyst formation in MDCK (Madin-Darby Canine Kidney) cells. This therefore demonstrates that, in the present invention, hypermethylation of PKD1 and regulator genes associated with cyst formation plays a decisive role in cyst formation and shows that the present invention can be used in therapeutic applications for autosomal dominant polycystic kidney disease.
Owner:SOOKMYUNG WOMENS UNIV IND ACADEMIC COOPERATION FOUND

Medicine composition for treating polycystic kidney disease and use thereof

The invention relates to a pharmaceutical composition for treating polycystic kidney disease. The active ingredients of the pharmaceutical composition comprise effective doses of thiazolidinediones and diuretics. The preferential combination is as follows: the thiazolidinediones are selected from rosiglitazone and the diuretics are selected from amiloride hydrochloride. The animal experiments prove that the efficacy of the composition of the rosiglitazone and the diuretics on the treatment of the polycystic kidney disease is better than the single use of one drug. The effect of the pharmaceutical composition for treating the polycystic kidney disease is better than the single use of one drug, thereby being a drug for treating the polycystic kidney disease and being worth expecting.
Owner:CHANGZHOU HI TECH DISTRICT MULTIPLE DIMENSION IND TECH INST

Kit for use in treatment of polycystic ovarian disease

InactiveUS6492177B1BiocideHormone peptidesPolycystic ovarian diseasePolycystic liver disease
Agents which increase the levels of human insulin-like growth factor-1 binding protein (h-ICFBP-1), such as an estrogen, are used in conjunction with a gonadotropin releasing hormone (GnRH) analogue in the treatment of PCOD and associated infertility.
Owner:LAB SERONO SA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products